Wasman Jane
Wasman Jane's purchase track record
Wasman Jane has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/30/2025 | SLS | $34K | +12.3% | -5.3% | +15.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
SLS Stock Fluctuates Amid M&A Speculation and New AML Study. SELLAS Life Sciences shares have seen volatile movement driven by retail investor speculation about potential M&A activity at the ASH conference. Recent news also highlights a new AML study that has fueled optimism among some investors regarding the company's pipeline. While the stock has experienced a recent rally, momentum has slowed, leaving it trading well below the average analyst target price.
Transaction History
| RIGL | ▲ Buy | Grant | 5,750 | $0 | 5/15/2026 | View on chart |
| SLS | ▲ Buy | Grant | 50,000 | $0 | 1/7/2026 | View on chart |
| SLS | ▲ Buy | Open Market | 20,000 | $34K | 5/30/2025 | View on chart |
| RIGL | ▲ Buy | Grant | 2,500 | $0 | 5/23/2025 | View on chart |
| SLS | ▲ Buy | Grant | 12,500 | $0 | 1/10/2025 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/25/2024 | View on chart |
| SLS | ▲ Buy | Grant | 6,000 | $0 | 1/22/2024 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/26/2023 | View on chart |
| SLS | ▲ Buy | Grant | 2,500 | $0 | 2/2/2023 | View on chart |
| RIGL | ▲ Buy | Grant | 25,000 | $0 | 5/20/2022 | View on chart |
| SLS | ▲ Buy | Grant | 1,900 | $0 | 1/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RIGL: No Recent Company-Specific News Identified
Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.
RIGL: No Recent Company-Specific News Identified. Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.